Sangamo Therapeutics, Inc.
SGMO
$0.5863
$0.01312.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 81.71M | 63.76M | 57.80M | 52.29M | 12.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 81.71M | 63.76M | 57.80M | 52.29M | 12.28M |
| Cost of Revenue | 103.30M | 100.44M | 111.52M | 138.75M | 168.11M |
| Gross Profit | -21.59M | -36.68M | -53.72M | -86.46M | -155.83M |
| SG&A Expenses | 37.55M | 40.52M | 42.22M | 45.66M | 50.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.85M | 140.95M | 153.75M | 184.41M | 219.04M |
| Operating Income | -59.14M | -77.20M | -95.95M | -132.12M | -206.76M |
| Income Before Tax | -63.50M | -79.60M | -98.11M | -134.85M | -248.51M |
| Income Tax Expenses | -193.00K | -146.00K | -167.00K | -12.00K | 1.17M |
| Earnings from Continuing Operations | -63.31 | -79.45 | -97.94 | -134.84 | -249.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.31M | -79.45M | -97.94M | -134.84M | -249.68M |
| EBIT | -59.14M | -77.20M | -95.95M | -132.12M | -206.76M |
| EBITDA | -54.67M | -72.48M | -90.84M | -126.43M | -196.79M |
| EPS Basic | -0.28 | -0.38 | -0.52 | -0.74 | -1.38 |
| Normalized Basic EPS | -0.16 | -0.22 | -0.29 | -0.44 | -0.68 |
| EPS Diluted | -0.29 | -0.39 | -0.53 | -0.75 | -1.38 |
| Normalized Diluted EPS | -0.17 | -0.22 | -0.30 | -0.44 | -0.68 |
| Average Basic Shares Outstanding | 895.75M | 842.75M | 802.82M | 770.25M | 739.08M |
| Average Diluted Shares Outstanding | 901.73M | 848.73M | 808.80M | 776.23M | 739.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |